oa-235i
Small moleculeexperimental
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jan 23, 2023 (NCT05680233)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Proteinase-activated receptor 2INHIBITOR
F2RL1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05680233 | Phase 1 | Jan 23, 2023 | Mayo Clinic, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Oasis Pharmaceuticals, LLC |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Mayo Clinic | Academic/Hospital | 1 | 0 | 1 | 2023 |
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Government | 1 | 0 | 1 | 2023 |
| Oasis Pharmaceuticals, LLC | For profit | 1 | 1 | 1 | 2023 |
3 organizations
Page 1 / 1